Research published by COTA found DLBCL patients who start treatment within two weeks of diagnosis face worse outcomes than ...

The company’s ENS-002 is aimed at treating atopic dermatitis. Credit: © 2024 Concerto Biosciences, Inc. All rights reserved.

GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...

MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

The key benefit of zerlasiran’s approach is its ability to directly target and silence the gene responsible for Lp(a) ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...